Intuitive Surgical opens the week with clear analyst support, shares in the NASDAQ-100 spotlight

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:04.

Intuitive Surgical (US46120E6023) enters the new trading week on Nasdaq with a solid earnings track record and a firmly positive analyst view. The medical-technology specialist is a long-standing member of the NASDAQ-100, underlining its role among US large caps.

What the estimates signal

For the current fiscal year, Wall Street expects Intuitive Surgical to deliver continued earnings growth, with consensus estimates compiled by several platforms pointing to higher full-year EPS compared with 2025, according to aggregated analyst data.MarketBeat earnings overview The company last reported first-quarter 2026 earnings on 21 April 2026, posting earnings per share of 2.50 US dollars, clearly above the consensus estimate of 2.08 dollars for the period.MarketBeat earnings overview

The revenue and procedure trends that underpinned that beat remain central to analyst models. Several research houses referenced in consensus compilations continue to expect stable demand for robotic-assisted surgery and a high utilisation of installed da Vinci systems when projecting Intuitive Surgical’s medium-term growth path.TradingKey financial health snapshot

Analyst view and recent price level

On price level, Intuitive Surgical shares most recently closed at around 402.90 US dollars on Nasdaq on 22 June 2026, after a marginal daily decline of just under 1 percent according to several quote services.TradingKey financial health snapshot That puts the stock markedly below the average analyst 12-month price objective of about 565 US dollars collected by one forecast platform, which compiles published targets from Wall Street research.PandaForecast analyst target compilation

The implied upside of more than 35 percent between the current quotation band and that average target reflects continued confidence in Intuitive Surgical’s competitive position. In aggregated ratings, a clear majority of analysts track the stock with recommendations in the Buy or equivalent Outperform range, while only a minority remains neutral.PandaForecast analyst target compilation

The product behind the stock

Intuitive Surgical generates the bulk of its revenue with the da Vinci robotic-assisted surgical system, including the sale of systems, instruments, accessories and service contracts. Hospitals typically purchase or lease the platforms and then pay recurring fees tied to the number of minimally invasive procedures performed.

Where the stock trades today

The Intuitive Surgical shares (US46120E6023) last traded on 2026-06-22, 16:00 Eastern Time on Nasdaq at 402.90 US dollars.

This article provides purely factual information and does not contain any investment advice, recommendation or solicitation to buy or sell securities. All data are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified financial adviser before making investment decisions.